Pre-Exposure Prophylaxis (PrEP) is a strategy that involves the use of anti-HIV medications (also called antiretrovirals, or ARVs) by HIV-negative individuals to reduce the risk of HIV infection via sexual exposure. In 2012, the US Food and Drug Administration (FDA) approved the drug, Truvada, for daily oral use as PrEP.
This project is a collaboration between HART and Callen-Lorde Community Health Center (CLCHC), the largest LGBT community health provider in New York City. The study is the first community-based demonstration project to be fully integrated into a community healthcare setting, and it is designed to evaluate a program in which PrEP is introduced, provided, and supported as part of a comprehensive prevention package. The project is also designed to identify and examine social and behavioral factors associated with disparities in access to prevention and care services among gay, bisexual, and other men who have sex with men in NYC that might direct or impact PrEP implementation programs and policies.
Click here to view the SPARK website
The National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Grant #: R01AA022067
Dates: 09/2012 - 07/2017
PI: Sarit A. Golub, PhD, MPH
At the present time, the only approved drug for Pre-Exposure Prophylaxis (PrEP) against HIV has been Truvada, a daily oral pill that reduces the risk of HIV infection via sexual exposure. However, several alternative forms of PrEP are making their way through human trials, including long-acting injectables.
READY is a project designed to evaluate the decision making processes of people who have already been taking PrEP for at least a year, to determine what factors they would consider in deciding what modality of PrEP to use as their HIV prevention strategy. Looking at these individuals’ experiences taking PrEP, their opinions and perceptions of alternative forms of PrEP (pills, shots, and IVs), and seeking guidance from this target population on how best to distribute long-acting injectable PrEP information and services, READY hopes to help clinicians and organizations be “ready” for these new forms of medical HIV prevention technologies as soon as they reach the market.
The National Institute of Mental Health (NIMH)
Grant #: R01MH106380
PI: Sarit A. Golub, PhD, MPH
In studies of risk behavior, we often assume that risk perceptions help drive the decisions people make. For example, risk perceptions are thought to be important in decisions about condom use (i.e., perceptions of the risk of contracting HIV or an STD), putting on a seat belt (i.e., perceptions of the risk of a car accident), or buying health insurance (i.e., perceptions of the risk of contracting an illness). However, the degree to which risk perceptions actually do factor into decision making - as well as the extent to which people are actually accurate in their risk perceptions - is largely unknown. The purpose of this project is to examine the accuracy of risk perceptions in an experimental setting and to quantify the relationship between risk perception and risk-taking behavior in an experimental task.